ASPIRE BIOPHARMA O.N.

Sublingual nano technology delivers caffeine rapidly to the blood stream, bringing its unique disruptive benefits to the Pre-workout market Initial production has commenced with six flavor options Expanded pre-launch consumer testing planned for Q2 2025 Aspire to launch BUZZ BOMB™ at two major upcoming fitness conventions Marketing plan focused on cost-effective multi-channel digital strategy targeting primary influencers, direct response sales and traditional retail sales channels Global pre-workout supplements market size is expected to reach $27.97 billion by 2030, registering a CAGR of 5.9% from 2025 to 2030 HUMACO, PUERTO RICO and NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced the brand name BUZZ BOMB™ and anticipated market launch for its novel sublingual pre-workout supplement. BUZZ BOMB™ features 50mg of caffeine and is designed to support sustained energy and mental focus, helping athletes and fitness enthusiasts maximize their performance potential.» Mehr auf accessnewswire.com

Trial marks key milestone in driving pipeline progress Phase 1 trial scheduled for completion mid-June 2025 Topline data from High-Dose Aspirin Trail anticipated early in 3Q with the potential to support an accelerated approval, subject to FDA feedback HUMACAO, PR and NEW YORK, NY / ACCESS Newswire / May 20, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that the first patient has been dosed in its Phase I single-center clinical trial in the United States designed to evaluate safety, pharmacokinetics and pharmacodynamics, of its lead therapeutic candidate, an oral transmucosal fast-acting high-dose aspirin formulation. The objectives of this Phase 1 single dose clinical study are to evaluate the safety, pharmacokinetics and pharmacodynamics of Aspire's sublingual aspirin powder and granules when administered orally in healthy adult volunteers.» Mehr auf accessnewswire.com

HUMACAO, PUERTO RICO AND NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), a developer of a multi-faceted patent-pending drug delivery technology, today announced that Kraig Higginson, Chief Executive Officer of Aspire, will be presenting at the upcoming Sidoti Virtual Investor Conference on May 21 at 2:30 PM Eastern. Investors and other interested individuals may access the virtual presentation here: https://sidoti.zoom.us/webinar/register/WN_q62DwzilROyKt-kOh_GJDQ One-on-One Meetings Inspire will also host virtual one-on-ones with investors on Wednesday, May 21 and Thursday, May 22, 2025.» Mehr auf accessnewswire.com